Clinical trials: CONTROL Condition
Mixed Dyslipidemia
Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed Dyslipidemia
EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting angiopoietin-like 3 protein (ANGPTL3), which may bring benefits for patients with dyslipidemia conditions.
- Trial name
- NCT07799129
- Testing
- EDP167 100mg, EDP167 200mg, EDP167 300mg
- Where
- 2 sites in China
- Volunteers
- 144 people
- Sponsor
- Eddingpharm (Zhuhai) Co., Ltd.
Diabetes, Healthy
Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects
This trial is conducted in Europe. The aim of this trial is to investigate safety, tolerability and pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the…
- Trial name
- NCT01865331
- Testing
- insulin degludec, insulin degludec/insulin aspart 50
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Alzheimer's Disease
AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)
The study will evaluate the safety \& efficacy of AC-1204, a ketogenic compound, administered orally on a daily basis for 6 months.
- Trial name
- ALERT (NCT01211782)
- Testing
- caprylic triglyceride, long-chain triglyceride
- Where
- United States
- Sponsor
- Cerecin
RSV Infection
Safety and Immunogenicity Study of SCB-1019T in Children
This phase 1 study in Australia will evaluate the safety, reactogenicity and immunogenicity of the Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T) in children 2-<6 years of age.
- Trial name
- NCT06666179
- Testing
- low dose SCB-1019T, adjuvanted low dose SCB-1019T, high dose SCB-1019T
- Where
- Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Type 2 Diabetes Mellitus
Bexagliflozin Efficacy and Safety Trial
The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events.
- Trial name
- BEST (NCT02558296)
- Testing
- Bexagliflozin
- Where
- 157 sites in United States, Canada and 8 more
- Volunteers
- 1,700 people
- Sponsor
- Theracos
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic control of liraglutide in combination with sulphonylurea agent (SU) compared to SU monotherapy, as assessed by HbA1c after 24 weeks and 52…
- Trial name
- NCT00395746
- Testing
- sulfonylurea, liraglutide
- Where
- Japan
- Volunteers
- 264 people
- Sponsor
- Novo Nordisk A/S
Respiratory Viral Infection
A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses
A clinical study to evaluate the efficacy and safety of once daily oral dosing of 100 mg AP1189 or placebo administered for 14 days, as an add-on to standard of care (SOC) in participants with respiratory insufficiency expected…
- Trial name
- RESPIRE (NCT07633288)
- Testing
- AP1189, 100 mg
- Where
- 11 sites in Bosnia and Herzegovina, Montenegro and 2 more
- Volunteers
- 96 people
- Sponsor
- SynAct Pharma Aps
Drug Safety
Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29
The novel humanized monoclonal antibody CaCP29 was developed to control the inflammatory response to various stimuli in humans and espacially during sepsis.
- Trial name
- NCT01319903
- Testing
- CaCP29, a humanized monoclonal antibody
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- InflaRx GmbH
Dry Eye Disease
Study to Evaluate the Efficacy and Safety of CKD-352
The purpose of this study is to compare the efficacy and safety of CKD-352 in patients with dry eye disease
- Trial name
- NCT04548427
- Testing
- CKD-352, Diquafosol Sodium 3%
- Where
- South Korea
- Volunteers
- 283 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus, Type 2
Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)
The purpose of the study is to assess how MK0767, compared to Metformin, performs in lowering blood glucose levels in patients whose Type II diabetes is not controlled by diet and exercise.
- Trial name
- NCT00543361
- Testing
- MK0767, Comparator: metformin
- Volunteers
- 382 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-alcoholic Steatohepatitis
Investigate Safety, Tolerability, PK/PK of J2H 1702 in Healthy Males
1. Research Purpose: To evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic properties of J2H-1702 (a candidate for treatment of non-alcoholic steatohepatitis) in healthy men. 2.
- Trial name
- NCT06308861
- Testing
- Single administration Amg dose Group, Single administration Bmg dose Group, Single administration Cmg dose Group
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- J2H Biotech
Dyslipidemia
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia.
- Trial name
- PURSUIT (NCT06173570)
- Testing
- AZD0780
- Where
- 55 sites in United States, Canada and 6 more
- Volunteers
- 428 people
- Sponsor
- AstraZeneca
OSA - Obstructive Sleep Apnea, Obesity
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy
The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA but not receiving PAP
- Trial name
- NCT07387094
- Testing
- XW003 injection
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Parkinson's Disease
Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off
The purpose of this study is to test the effects of carbidopa/levodopa/entacapone compared to the effects of immediate-release carbidopa/levodopa on non-motor symptoms of end-of-dose wearing off in persons who have Parkinson's…
- Trial name
- NCT00642356
- Testing
- Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa
- Where
- 21 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis
Primary Insomnia
Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia
A six-month study to determine the safety and efficacy with an additional open-label extension to determine the long-term safety of eszopiclone in the treatment of adult subjects with primary insomnia.
- Trial name
- NCT01710631
- Testing
- eszopiclone 3 mg
- Volunteers
- 791 people
- Sponsor
- Sumitomo Pharma America, Inc.
Atrial Fibrillation
Subtherapeutic INR Levels in Patients With AVK: Incidence, Associated Factors, Prognosis and Control Strategies
This prospective observational study is to assess the predictive factors of poor control of international normalized ratio (INR) to determine the treatment strategies received by patients with a poor control of INR in real-life…
- Trial name
- SULTAN (NCT02610153)
- Testing
- Vitamin K Antagonist
- Where
- Spain
- Volunteers
- 1,013 people
- Sponsor
- Bayer
Macular Edema Secondary to Central Retinal Vein Occlusion
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
This is a phase 3 study to determine the efficacy of VEGF Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion.
- Trial name
- NCT00943072
- Testing
- VEGF Trap-Eye 2.0mg
- Where
- 61 sites in United States, Canada and 3 more
- Volunteers
- 189 people
- Sponsor
- Regeneron Pharmaceuticals
Presbyopia
An Evaluation of the Safety of CSF-1 in Presbyopic Subjects
This is a multi-center, double-masked, vehicle-controlled study. The purpose of the study is to evaluate the safety of CSF-1 compared with vehicle in presbyopic subjects. Subjects will be treated for at least 6 weeks.
- Trial name
- NCT05393895
- Testing
- CSF-1, Vehicle
- Where
- 12 sites in United States
- Volunteers
- 178 people
- Sponsor
- Orasis Pharmaceuticals Ltd.
Asthma
Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild Asthma
In both parts, the primary comparisons of interest are between the percentage of patients with drug-related adverse events at each dose and placebo during single and multiple dosing regimens.
- Trial name
- NCT03971539
- Testing
- BI 894416
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Boehringer Ingelheim
Encephalitis, Tick-Borne
Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children
The purpose of this study is to evaluate the safety, immunogenicity and tolerability of TBE vaccines administered to children.
- Trial name
- NCT00311441
- Testing
- Tick-Borne Encephalitis vaccine
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.